Baby step or giant leap?: Parties' expanded access to documentary evidence under the new Japanese code of civil procedure

Harvard International Law Journal

Volumn 40, Issue 1, 1999, Pages

  Mochizuki, Toshiro M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043264115     PISSN: 00178063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. See Madoka Sakamoto, Shōko shūshū seido no kaikaku wo megutte [Regarding the reforms to the evidence collection system], JIYŪ TO SEIGI, July 1997, at 76; Tsuneharu Yonemaru, Seiyaku gaisha no fuhō kōi sekinin kuni no kantoku sekinin [Pharmaceutical companies' tort liability, the national government's supervisory responsibility], in HORITSUGAKU GA WAKARU 120, 120 (AERA Mook No. 16, 1996). The number represents approximately 40% of Japan's 5000 hemophiliacs. See Takehisa Awaji, The HIV Litigation and its Settlement {in Japan}, 6 PAC. RIM L. & POL'Y J. 581, 581-82 (Keisuke Mark Abe trans., 1997).
2. See Madoka Sakamoto, Shōko shūshū seido no kaikaku wo megutte [Regarding the reforms to the evidence collection system], JIYŪ TO SEIGI, July 1997, at 76; Tsuneharu Yonemaru, Seiyaku gaisha no fuhō kōi sekinin kuni no kantoku sekinin [Pharmaceutical companies' tort liability, the national government's supervisory responsibility], in HORITSUGAKU GA WAKARU 120, 120 (AERA Mook No. 16, 1996). The number represents approximately 40% of Japan's 5000 hemophiliacs. See Takehisa Awaji, The HIV Litigation and its Settlement {in Japan}, 6 PAC. RIM L. & POL'Y J. 581, 581-82 (Keisuke Mark Abe trans., 1997).
3. See Madoka Sakamoto, Shōko shūshū seido no kaikaku wo megutte [Regarding the reforms to the evidence collection system], JIYŪ TO SEIGI, July 1997, at 76; Tsuneharu Yonemaru, Seiyaku gaisha no fuhō kōi sekinin kuni no kantoku sekinin [Pharmaceutical companies' tort liability, the national government's supervisory responsibility], in HORITSUGAKU GA WAKARU 120, 120 (AERA Mook No. 16, 1996). The number represents approximately 40% of Japan's 5000 hemophiliacs. See Takehisa Awaji, The HIV Litigation and its Settlement {in Japan}, 6 PAC. RIM L. & POL'Y J. 581, 581-82 (Keisuke Mark Abe trans., 1997).
4. See Sakamoto, supra note 1, at 76.
5. See Awaji, supra note 1, at 582; Sakamoto, supra note 1, at 76.
6. See Sakamoto, supra note 1, at 76. The settlement included payments of 45 million yen to each plaintiff, a monthly medical expenses payment of 150,000 yen to each person who had become symptomatic, and promises by the defendant to endeavor to prevent a similar outbreak from occurring. See Yonemaru, supra note 1, at 122.
7. Cf. Awaji, supra note 1, at 591-95 (discussing the courts' findings regarding the defendants' awareness of the threat of HIV at the relevant time).